As the prevalence of type 2 diabetes increases worldwide, we find that more research is undertaken to help people manage their diabetes well and to prevent complications. A number of new medications have been released in the last 10 years. 90% of the people with Type 2 diabetes are either overweight or obese. We all know that weight loss helps to improve blood sugar control and in some can completely reverse type 2 diabetes. In the recent past medications for diabetes are geared to not only reduce blood glucose but also address weight gain.

Here we describe a new medication called Semaglutide, which is GLP-1 (Glucagon Like Peptide-1) analogue.

GLP-1 is a natural hormone that has multiple actions in glucose and appetite regulation. Blood glucose and appetite is mediated by changes happening in the pancreas and the brain. The hormone Glucagon like Peptide or GLP-1 plays a major role.

GLP-1 reduces blood glucose in a glucose dependent manner by stimulating insulin secretion, which means GLP-1 works only when blood glucose is high and does not stimulate insulin secretion when blood glucose is low.

To find out more about Semaglutide, click on the link below:

Semaglutide (Ozempic): A new medication for Type 2 diabetes management

Dr Chinnadorai Rajeswaran is a consultant Physician specialising in Endocrinology, Diabetes and Obesity. As a private endocrinologist he  has private endocrine, diabetes and weight loss clinics in Harley Street, London, Chennai (India), Claremont Hospital, Sheffield, Nuffield Hospital, Leeds and Simplyweight, Bradford.

He has face to face consultations with people from Barnsley, Rotherham, Chesterfield, Doncaster, Wakefield, Huddersfield, Bradford, Harrogate, Leeds, Sheffield, London and Chennai (India). He also offers video consultations.